These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
313 related items for PubMed ID: 29428550
1. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma. Leão R, Nayan M, Punjani N, Jewett MAS, Fadaak K, Garisto J, Lewin J, Atenafu EG, Sweet J, Anson-Cartwright L, Boström P, Chung P, Warde P, Bedard PL, Bagrodia A, Freifeld Y, Power N, Winquist E, Hamilton RJ. Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550 [Abstract] [Full Text] [Related]
2. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer. Paffenholz P, Nestler T, Hoier S, Pfister D, Hellmich M, Heidenreich A. Urol Oncol; 2019 Nov; 37(11):809.e9-809.e18. PubMed ID: 31540832 [Abstract] [Full Text] [Related]
3. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study. Dusaud M, Malavaud B, Bayoud Y, Sebe P, Hoepffner JL, Salomon L, Houlgatte A, Pignot G, Rigaud J, Fléchon A, Pfister C, Rouprêt M, Soulié M, Méjean A, Durand X. J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263 [Abstract] [Full Text] [Related]
4. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection. Baessler B, Nestler T, Pinto Dos Santos D, Paffenholz P, Zeuch V, Pfister D, Maintz D, Heidenreich A. Eur Radiol; 2020 Apr; 30(4):2334-2345. PubMed ID: 31828413 [Abstract] [Full Text] [Related]
5. [Efficacy of modified retroperitoneal lymph node dissection for testicular nonseminomatous germ cell tumors]. Liu ZW, Zhou FJ, Han H, Qin ZK, Yu SL, Li YH, Ye YL, Teng XY. Ai Zheng; 2008 Dec; 27(12):1302-6. PubMed ID: 19079998 [Abstract] [Full Text] [Related]
6. Robotic Postchemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. Li R, Duplisea JJ, Petros FG, González GMN, Tu SM, Karam JA, Huynh TT, Ward JF. Eur Urol Oncol; 2021 Aug; 4(4):651-658. PubMed ID: 31412007 [Abstract] [Full Text] [Related]
7. Serum miRNA Predicts Viable Disease after Chemotherapy in Patients with Testicular Nonseminoma Germ Cell Tumor. Leão R, van Agthoven T, Figueiredo A, Jewett MAS, Fadaak K, Sweet J, Ahmad AE, Anson-Cartwright L, Chung P, Hansen A, Warde P, Castelo-Branco P, O'Malley M, Bedard PL, Looijenga LHJ, Hamilton RJ. J Urol; 2018 Jul; 200(1):126-135. PubMed ID: 29474847 [Abstract] [Full Text] [Related]
10. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis]. Li XD, Guo SJ, Chen SL, Liu ZF, Dong P, Zhang ZL, Jiang LJ, Yao K, Li YH, Han H, Qin ZK, Liu ZW, Zhou FJ. Zhonghua Wai Ke Za Zhi; 2017 Aug 01; 55(8):603-607. PubMed ID: 28789511 [Abstract] [Full Text] [Related]
11. Percentage of Teratoma in Orchiectomy and Risk of Retroperitoneal Teratoma at the Time of Postchemotherapy Retroperitoneal Lymph Node Dissection in Germ Cell Tumors. Calaway AC, Kern SQ, Crook D, Tong Y, Masterson TA, Adra N, Einhorn LH, Foster RS, Cary C. J Urol; 2021 Dec 01; 206(6):1430-1437. PubMed ID: 34288715 [Abstract] [Full Text] [Related]
15. Patient selection for retroperitoneal lymph node dissection after chemotherapy for nonseminomatous germ cell tumors. Herr HW, Toner GC, Geller NL, Bosl GJ. Eur Urol; 1991 May 01; 19(1):1-5. PubMed ID: 1848821 [Abstract] [Full Text] [Related]
16. Predicting retroperitoneal histology in postchemotherapy testicular germ cell cancer: a model update and multicentre validation with more than 1000 patients. Vergouwe Y, Steyerberg EW, Foster RS, Sleijfer DT, Fosså SD, Gerl A, de Wit R, Roberts JT, Habbema JD. Eur Urol; 2007 Feb 01; 51(2):424-32. PubMed ID: 16911854 [Abstract] [Full Text] [Related]
17. Postchemotherapy laparoscopic retroperitoneal lymph node dissection for low-volume, stage II, nonseminomatous germ cell tumor: first 100 patients. Steiner H, Leonhartsberger N, Stoehr B, Peschel R, Pichler R. Eur Urol; 2013 Jun 01; 63(6):1013-7. PubMed ID: 23021090 [Abstract] [Full Text] [Related]
18. Clinical impact of residual extraretroperitoneal masses in patients with advanced nonseminomatous germ cell testicular cancer. Masterson TA, Shayegan B, Carver BS, Bajorin DF, Feldman DR, Motzer RJ, Bosl GJ, Sheinfeld J. Urology; 2012 Jan 01; 79(1):156-9. PubMed ID: 22202548 [Abstract] [Full Text] [Related]
19. Contemporary management of postchemotherapy testis cancer. Daneshmand S, Albers P, Fosså SD, Heidenreich A, Kollmannsberger C, Krege S, Nichols C, Oldenburg J, Wood L. Eur Urol; 2012 Nov 01; 62(5):867-76. PubMed ID: 22938868 [Abstract] [Full Text] [Related]
20. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters? Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Cancer; 2006 Oct 01; 107(7):1503-10. PubMed ID: 16944534 [Abstract] [Full Text] [Related] Page: [Next] [New Search]